Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03250767 · ClinicalTrials.gov registry record
Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement
A clinical trial, sponsored by Smith & Nephew.
- Terminated
- Registry status
- 58
- Enrollment target
NCT03250767: Clinical Trial study, sponsored by Smith & Nephew.
NCT03250767 is a clinical trial that was terminated before completion, run by Smith & Nephew. The registered enrollment target is 58 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03250767 was terminated before completion, sponsored by Smith & Nephew.
- TERMINATED
- Registry status
- 58 participants
- Enrollment target
Study Summary
A post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the Titan Modular Shoulder System 2.5 when used for primary shoulder arthroplasty.
Primary Outcome
Implant survivorship defined as absence of device removal or revision
Interventions
- DEVICE Integra Titan Modular Shoulder System 2.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2023-03-10 |
Why NCT03250767 stopped before completion
NCT03250767 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 58 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Integra Titan Modular Shoulder System 2.5 is the first listed.
NCT03250767 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03250767 about?
NCT03250767 is a clinical study titled "Clinical Evaluation of the Integra® Titan™ Modular Shoulder System Generation 2.5 for Primary Shoulder Joint Replacement". A post market, prospective, non-randomized, multi-center, open-label, clinical study using survivorship as the reference performance goal to study the safety and efficacy of the Titan Modular Shoulder System 2.5 when used for primary shoulder arthroplasty.
What is the current status of trial NCT03250767?
This trial is currently terminated. The enrollment target is 58 participants. The study started on 2017-08-01. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT03250767?
The interventions under investigation include: Integra Titan Modular Shoulder System 2.5 (DEVICE).
Who is sponsoring clinical trial NCT03250767?
This trial is sponsored by Smith & Nephew, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI